ArticleJournal of neuro-oncology2025
Education paths in neuro-oncology: combining technical skills with multidisciplinary care. A survey from the AINO (Italian Association for Neuro-Oncology) Youngster Committee.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Irreversible blindness from hydrocephalus in recurrent pediatric pilocytic astrocytoma: a case report.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNeuro-oncology is a multidisciplinary subspecialty that has evolved and expanded tremendously over the last 20 years. In Europe, notwithstanding a number of commendable initiatives, neither a specific neuro-oncology training curriculum nor a consensus on the ideal training tools have been set. In this context, the Youngster Committee of the Italian Association for Neuro-Oncology (AINO) has run a nationwide survey to take a snapshot of the current situation of neuro-oncology education in Italy.
methodsBetween July and November 2023, we distributed through AINO a 34-question survey addressed to all Italian care providers dealing with neuro-oncology, irrespective of specialty and level of experience, as per AINO mission. The questionnaire was disseminated using an open link. We analyzed and stratified answers according to epidemiological characteristics of the respondents, i.e. age, gender, role, years of experience, type and case load of their work Institutions, geographical region.
resultsWe collected 254 valid questionnaires. The majority of respondents were under 40 years old (62.6%); neurosurgeons formed the largest specialty group (48%). Residency was a key step for neuro-oncology education according to 33% of participants; notably, younger respondents gave a significantly more positive assessment of residency programs compared to older ones (72% vs. 56%, p = 0.0193). PhD programs in Italy are focused only on research, according to 30% of respondents. Regarding the tools for continuing medical education in neuro-oncology, a striking contrast between the ideal ones, which should be the frequent participation in dedicated courses (59% responses), and the actual one, which is scientific literature (55%), was recorded. Mentorship programs are rare and inconsistent and should be strengthened. More than 90% of participants declared multidisciplinary collaboration as fundamental. Multispecialty societies like AINO have a key role in strengthening education in neuro-oncology through the organization of structured post-graduate programs.
conclusionThe results of this survey, by describing the status of the neuro-oncology training paths in Italy, can lay the foundation for initiatives aimed at harmonizing neuro-oncology education in Italy and Europe. The creation of a shared neuro-oncology curriculum and of a network of mentors is suggested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.